Perceive Biotherapeutics, Inc., a South San Francisco-based biotechnology company developing investigational ophthalmic gene therapies, has completed enrollment in the Phase 2a portion of its JOURNEY clinical trial evaluating VOY-101 for geographic atrophy secondary to age-related macular degeneration. Announced on October 9, 2026, the study enrolled 47 participants representing 94 eyes, exceeding its original target of 62 eyes, with topline results from the 15-month primary efficacy endpoint expected in late 2027.
The enrollment milestone advances a therapeutic strategy designed to restore local regulation of the complement system through a single intravitreal injection. Unlike currently approved United States treatments for geographic atrophy, which require repeated injections, VOY-101 uses an adeno-associated viral vector to deliver genetic instructions for sustained production of a protective form of complement factor H. However, the company has not announced new efficacy findings, and the treatment’s ability to provide durable disease modification remains unproven in patients.
Perceive Biotherapeutics also appointed Tony Gibney, a former senior executive at Iveric Bio and Aura Biosciences, as an independent director. His appointment brings experience in ophthalmology commercialization, complement-targeted therapies and biotechnology transactions as the company prepares for its next clinical milestone. The combination of completed enrollment and board expansion strengthens the company’s development preparations, but the more consequential test will be whether VOY-101 measurably slows retinal degeneration without introducing unacceptable ocular or systemic risks.
How does the JOURNEY Phase 2a trial assess VOY-101 against untreated fellow eyes?
The JOURNEY study, formally identified as PBI-AMD-002 and registered under NCT06087458, is a prospective, multicentre Phase 1/2a clinical programme involving patients with advanced non-neovascular age-related macular degeneration. Its initial Phase 1 portion evaluated escalating doses of VOY-101 to assess safety and establish a recommended Phase 2 dose. The subsequent Phase 2a portion uses a randomized, open-label, fellow-eye-controlled design to investigate efficacy and further characterize safety.
Participants in Phase 2a have geographic atrophy affecting both eyes, with lesions selected for similarity in size. One eye is randomly assigned to receive a single intravitreal injection of VOY-101, while the other remains untreated and serves as the within-patient comparator. This design helps control for characteristics shared between the eyes, including age, genetic background and systemic environmental exposures.
The trial’s primary endpoint measures the change in geographic atrophy lesion size at Month 15. Secondary assessments include lesion progression through Month 24, best-corrected visual acuity, low-luminance visual function, development of macular neovascularization and treatment-related adverse events. Participants will be followed for 24 months, allowing investigators to examine whether any anatomical treatment effect persists beyond the primary assessment.
The increase from 62 planned eyes to 94 enrolled eyes represents approximately 52% more eyes than originally targeted. However, the 94 eyes belong to 47 participants and should not be treated as 94 statistically independent patients. The paired-eye design can improve control of patient-level variation, but the analysis must still account for differences between eyes and the correlation of measurements within individuals.
Why is complement factor H an important target for geographic atrophy gene therapy?
Geographic atrophy involves progressive degeneration of the retinal pigment epithelium and photoreceptors, which can eventually result in irreversible central vision impairment. The complement system, an important component of innate immunity, has been implicated in the inflammatory processes associated with age-related macular degeneration. Genetic studies have identified variations in complement-related genes, including complement factor H, that influence susceptibility to the disease.
Complement factor H acts as a regulatory protein that helps limit excessive activation of the alternative complement pathway. Certain genetic variants can impair protective regulation, contributing to a biological environment in which complement-associated inflammation may damage retinal tissues. This relationship provides the scientific basis for exploring whether restoring protective complement factor H activity could influence disease progression.
VOY-101 uses a recombinant adeno-associated viral vector encoding a form of a protective complement factor H variant. After intravitreal administration, the treatment is intended to produce sustained expression of the therapeutic protein within the eye. Rather than permanently correcting a patient’s original genetic sequence, the approach seeks to supplement local complement regulation through expression of a protective protein.
The therapeutic hypothesis is biologically relevant, but genetic association alone does not prove that replacing or supplementing complement factor H will slow geographic atrophy in patients. The treatment must generate sufficient local protein expression, reach appropriate ocular compartments and modify disease-related biological activity without producing excessive inflammation. JOURNEY is designed to begin testing whether that mechanism produces a measurable effect on retinal degeneration.
Could a single VOY-101 injection replace repeated geographic atrophy treatments?
The potential reduction in treatment frequency is central to VOY-101’s development strategy. Currently approved United States medicines for geographic atrophy require repeated intravitreal injections, creating continuing treatment appointments and monitoring requirements for patients and ophthalmology practices. A gene therapy capable of maintaining an appropriate biological effect after one administration could offer a different approach to long-term disease management.
Perceive Biotherapeutics is developing VOY-101 as a potentially one-time treatment because the viral vector is intended to sustain production of the therapeutic protein. This differs from conventional injected medicines whose pharmacological effects decline over time and require subsequent doses. However, the duration and consistency of clinically meaningful complement factor H expression have not yet been established through the completed Phase 2a study.
Durability is especially important because geographic atrophy progresses over years rather than weeks. A treatment that initially changes complement activity but loses sufficient effect after several months may not provide the intended practical advantage over existing medicines. Conversely, sustained expression requires careful long-term safety evaluation because the biological activity may continue after administration.
The distinction between a single administration and proven one-time disease control should remain clear. VOY-101 is administered once under the current study protocol, but that does not establish that patients would never require additional treatment or that a single injection would provide lifelong protection. The late-2027 results will provide an initial assessment of sustained anatomical efficacy, while longer follow-up will remain important for evaluating the durability of the treatment approach.
What clinical evidence must VOY-101 demonstrate beyond slowing geographic atrophy lesion growth?
The Phase 2a primary endpoint examines changes in geographic atrophy lesion size, a structural measurement commonly used in ophthalmic clinical trials. Retinal imaging can quantify the expansion of atrophic regions over time, providing an objective method for comparing disease progression between treatment groups. A smaller increase in lesion area among treated eyes would support a biological treatment effect, provided the difference is sufficiently robust and statistically credible.
However, a reduction in lesion growth does not automatically establish improved vision or reduced disability. Patients may experience different functional consequences depending on the location of atrophy, involvement of the central macula and the condition of surviving retinal tissue. A treatment that slows expansion in peripheral portions of a lesion may produce a different clinical experience from one that preserves tissue directly involved in central vision.
JOURNEY includes visual acuity and functional assessments that can help investigate these relationships. Measurements of best-corrected visual acuity and low-luminance vision may provide information about changes in visual performance, although the study’s size and follow-up duration could limit its ability to detect differences in some outcomes. These secondary measurements will therefore be important when interpreting the primary anatomical result.
The open-label design also requires appropriate attention to possible assessment bias. Although imaging measurements can be more objective than subjective symptoms, robust image acquisition, grading and statistical analysis remain important. The company has not announced the full analysis methodology or detailed Phase 2a results, so the reliability of any eventual treatment effect will need to be assessed when the data become available.
What safety concerns must Perceive Biotherapeutics address with intravitreal AAV gene therapy?
The potential for long-lasting biological activity creates a different safety profile from that of medicines requiring repeated dosing. Adeno-associated viral gene therapies can provoke immune responses against viral components or proteins produced after gene transfer, depending on the vector, dose and route of administration. Ocular inflammation and the consequences of unintended tissue exposure are therefore relevant considerations during clinical development.
Intravitreal administration avoids the surgical steps associated with subretinal gene therapy delivery, but it does not eliminate procedural risks. Intravitreal injections can be associated with infection, inflammation, increased intraocular pressure and other ocular complications. Gene therapy introduces additional questions involving the body’s immune response to the vector and the persistence of transgene expression.
The JOURNEY study explicitly monitors ocular and systemic safety, including inflammatory findings and development of macular neovascularization. The latter is important because geographic atrophy can coexist with, or progress alongside, neovascular forms of age-related macular degeneration. Development of abnormal blood vessels could complicate treatment and influence visual outcomes independently of changes in atrophic lesion growth.
Perceive Biotherapeutics has established a recommended Phase 2 dose following the earlier dose-escalation portion of the programme. That progression indicates that the company selected a dose for further investigation, but the October announcement did not provide detailed Phase 1 adverse-event rates or establish a comprehensive safety profile. The expanded Phase 2a population and 24-month follow-up should provide additional information, although uncommon or delayed complications may require substantially larger and longer studies.
How does VOY-101 compare with approved Syfovre and Izervay treatments?
The current United States geographic atrophy treatment market includes Syfovre (pegcetacoplan), marketed by Apellis Pharmaceuticals, and Izervay (avacincaptad pegol), marketed by Astellas Pharma following its acquisition of Iveric Bio. Both are complement inhibitors approved by the United States Food and Drug Administration in 2023. They target different components of the complement cascade and require continuing intravitreal administration.
Syfovre inhibits complement component C3 and can be administered every 25 to 60 days under its approved prescribing information. Izervay targets complement component C5 and is administered approximately once monthly. Both medicines have demonstrated reductions in geographic atrophy lesion growth in clinical trials, although they have not established restoration of vision already lost to retinal atrophy.
VOY-101 differs mechanistically by attempting to enhance the eye’s own complement regulatory capacity through sustained production of a protective form of complement factor H. Its single-injection design could also distinguish it from the recurring treatment schedules associated with approved complement inhibitors. These differences establish a potential development rationale, but they do not demonstrate better efficacy, greater safety or a superior risk-benefit profile.
The approved medicines also provide an important reference point for safety expectations. Their prescribing information identifies risks including ocular inflammation, development of neovascular age-related macular degeneration and injection-related complications. Syfovre additionally carries warnings concerning retinal vasculitis and retinal vascular occlusion, illustrating the importance of evaluating uncommon but potentially serious ocular events.
VOY-101 has not been compared directly with either marketed product in JOURNEY. The trial uses an untreated fellow eye as its comparator, meaning future efficacy percentages cannot reliably be ranked against results from unrelated studies without accounting for differences in disease characteristics, lesion location and follow-up duration. Direct comparative evidence would be valuable if VOY-101 progresses toward late-stage development.
Why could European regulatory scrutiny affect the future commercial outlook for VOY-101?
The geographic atrophy market has already demonstrated that regulatory acceptance can differ significantly between jurisdictions. While Syfovre and Izervay received United States approvals, the European Medicines Agency did not recommend authorisation of either product. The agency confirmed a negative opinion on Syfovre in 2024, while the application for Izervay, submitted under the name Izelvay in Europe, was withdrawn following regulatory concerns.
A central issue involved whether reductions in geographic atrophy lesion growth translated into clinically meaningful benefits for patients. European regulators concluded that the available evidence did not adequately establish benefits sufficient to outweigh the relevant treatment risks. Those decisions are particularly relevant to future therapies relying heavily on anatomical endpoints.
Perceive Biotherapeutics’ use of lesion-size change as its primary Phase 2a endpoint is scientifically appropriate for investigating an early efficacy signal, but future regulatory development may require more extensive evidence. Meaningful visual function measurements, treatment durability and a convincing safety profile could be important in demonstrating the value of an intervention designed to remain active for an extended period.
The potential commercial opportunity extends beyond the United States, particularly because access to approved disease-modifying treatments for geographic atrophy remains limited internationally. Nevertheless, the company’s global development prospects cannot be inferred solely from the size of the affected population. Regional approval requirements, healthcare budgets, clinical evidence standards and the eventual economics of gene therapy would determine the practical scope of any launch.
How does VOY-101 fit into the emerging competitive landscape for geographic atrophy gene therapy?
Perceive Biotherapeutics is not the only company investigating whether gene therapy can reduce the need for repeated treatment of geographic atrophy. Ocugen is developing OCU410, an investigational modifier gene therapy based on the RORA transcription factor, and began dosing patients in its Phase 3 ArMaDa3 trial in September 2026. That programme uses subretinal administration and addresses several disease-related pathways through a mechanism different from VOY-101.
The progress of OCU410 demonstrates that the gene therapy field is becoming increasingly competitive. Its advancement into Phase 3 also illustrates the scale of clinical evidence that may eventually be required before such products can reach the market. However, the separate programmes cannot be compared directly on efficacy or safety because they involve different biological targets, delivery approaches and development designs.
Intravitreal delivery could provide a practical advantage for VOY-101 if the treatment demonstrates adequate therapeutic expression and appropriate safety. Retina specialists routinely perform intravitreal injections, whereas subretinal administration generally requires more involved surgical procedures and specialised capabilities. Nevertheless, route of administration alone does not determine clinical effectiveness, and successful delivery to the relevant retinal tissues must be demonstrated.
The commercial value of the approach will depend on whether a single administration can deliver sustained benefit while reducing the overall treatment burden. Manufacturing consistency, vector supply, patient eligibility and long-term follow-up requirements would also influence implementation. These considerations become particularly important for treatments intended to provide prolonged biological effects after a single procedure.
Why does Tony Gibney’s appointment matter as Perceive Bio approaches its next development phase?
Tony Gibney joins Perceive Biotherapeutics as an independent director with more than three decades of experience in biotechnology finance, business development and corporate strategy. He most recently served as Chief Financial and Business Officer of Aura Biosciences, an ophthalmic oncology biotechnology company. His earlier experience includes serving as Executive Vice President and Chief Business and Strategy Officer of Iveric Bio before its acquisition by Astellas Pharma in 2023.
His involvement with Iveric Bio is particularly relevant because that company developed Izervay, one of the first United States-approved complement inhibitors for geographic atrophy. Experience with the regulatory, commercial and strategic challenges surrounding an approved retinal medicine could be useful as Perceive Biotherapeutics evaluates subsequent development decisions. However, the appointment does not establish a development partnership with Iveric Bio or Astellas Pharma.
Gibney previously held senior positions at Fog Pharmaceuticals, now Parabilis Medicines, and Achillion Pharmaceuticals, and worked in biotechnology investment banking at Leerink Partners and Merrill Lynch. He currently serves on the boards of LAPIX Therapeutics and InflaRx. These roles provide experience spanning corporate transactions, financing and development-stage biotechnology operations.
Perceive Biotherapeutics is privately held and backed by investors including Deerfield Management, Johnson & Johnson Innovation, GV, Braidwell, Gund Vision Fund and Catalio Capital Management. The October announcement did not disclose a new financing round, updated cash position or estimated development runway. The board appointment may strengthen strategic oversight, but it should not be interpreted as evidence that a financing or corporate transaction is imminent.
What will determine whether VOY-101 can progress beyond Phase 2a development?
The next major milestone is the planned late-2027 topline analysis of geographic atrophy lesion progression at Month 15. A credible efficacy signal would need to demonstrate a treatment-associated difference between injected and untreated eyes, supported by an appropriate statistical analysis and consistency across relevant disease characteristics. The magnitude of any effect will be as important as its statistical significance when assessing clinical relevance.
The safety findings will carry equal weight. A therapy intended to generate prolonged protein expression must demonstrate that its biological activity can be maintained without unacceptable ocular inflammation, retinal damage or other complications. Additional data through Month 24 will help assess persistence of effect and the relationship between anatomical outcomes and visual function.
Positive Phase 2a results would not establish that VOY-101 is ready for commercial use. Perceive Biotherapeutics would still need to determine the appropriate late-stage clinical programme, potentially including larger controlled studies, additional safety monitoring and discussions with regulators about acceptable efficacy endpoints. Manufacturing requirements associated with adeno-associated viral vectors would add another important development consideration.
The company estimates that geographic atrophy affects more than 1.5 million people in the United States, based on an extrapolation of earlier epidemiological research to a larger older population. That figure illustrates potential disease burden rather than the number of patients eligible for VOY-101. The study’s requirement for selected genetic characteristics and bilateral, suitably matched geographic atrophy lesions also means its enrolled population may not represent everyone diagnosed with the condition.
For Perceive Biotherapeutics, completing enrollment removes an important operational uncertainty and establishes a clearer timetable for evaluating its complement factor H gene therapy strategy. The study’s 47 participants provide an opportunity to investigate whether sustained genetic delivery can reduce geographic atrophy progression without the repeated injections required by currently approved medicines. The late-2027 readout will determine whether this approach has generated sufficiently convincing anatomical and safety evidence to justify the investment and clinical work required for larger trials.
